CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

Mar 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-03-01

Reporting Person: Feldman Eric Jay (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	50498	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$11.97	2029-04-16	Common Stock (53000)		Direct
Employee Stock Option (right to buy)	$4.72	2030-01-21	Common Stock (38000)		Direct
Employee Stock Option (right to buy)	$3.81	2031-01-19	Common Stock (20000)		Direct
Employee Stock Option (right to buy)	$3.85	2031-02-18	Common Stock (49000)		Direct

Footnotes

F1: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2: One-fourth of the shares vested on April 17, 2020; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

F3: One-fourth of the shares vested on January 22, 2021; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

F4: One-fourth of the shares vest on January 20, 2022; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

F5: One-fourth of the shares vest on February 19, 2022; the balance of the shares vest in a series of thirty-six successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.